drugset / Trial / NCT05612074

Methemoglobin Concentration in High Dose Inhaled Nitric Oxide

NCT05612074

Phase 0 Active not recruiting 10 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelBasic science

Summary

The goal of this clinical trial is to learn about the kinetic of methemoglobin in healthy subjects breathing high dose inhaled nitric oxide. The main questions it aims to answer are: * What are the kinetics of methemoglobin formation at a maximum of 300 parts per million of nitric oxide and oxygen * What are the kinetics of methemoglobin reduction after nitric oxide discontinuation Participants will be exposed to intermittent high dose inhaled nitric oxide at a maximum of 300 parts per million while being continuously monitored.

Timeline

Start
2023-10-16
Primary completion
2026-11
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 300 ppm Inhaled

Indications

No indication recorded.